Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AIM Act Touted As One Solution To Device Reimbursement Woes

This article was originally published in The Gray Sheet

Executive Summary

The Accelerating Innovation in Medicine Act, introduced last year with some bipartisan support, was touted at the latest House 21st Century Cures hearing as a self-pay path for seniors to get access to newly-approved devices not yet covered under Medicare, and to give manufacturers time to collect needed data to support reimbursement.

You may also be interested in...

Shortened ‘Cures’ Draft Retains Breakthrough Pathway, Device Reforms

But the April 29 updated draft of the broad-based House reform package for medical innovation is missing some significant items floated earlier this year, including a Medicare breakthrough device program, a revamp of diagnostics regulations and device supply-chain security reform.

Device Industry Grab-Bag Of Provisions In 21st Century Cures Draft

Device industry advocates have a lot of reading to do. There are more than two dozen provisions with relevance to the medtech sector, many aimed at smoothing the way for product approvals and reimbursement, in a 21st Century Cures discussion draft unveiled by the House Energy and Commerce panel Jan. 27. The initial proposal does not have bipartisan support.

Device Consortium Addresses Barriers To Early U.S. Feasibility Studies, MDIC’s Murray Tells Congress

Medical Device Innovation Consortium President and CEO Bill Murray testified about MDIC and FDA’s plans to promote early feasibility studies of products in the U.S., rather than abroad, at a recent House Energy and Commerce panel hearing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts